Skip to Content

Ipilimumab Disease Interactions

There are 7 disease interactions with ipilimumab:

Major

Ipilimumab (applies to ipilimumab) dermatitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Allergies, Dermatitis Herpetiformis

Immune-mediated dermatitis, including fatal cases, have occurred with ipilimumab therapy. Monitor patients for signs and symptoms of dermatitis, such as rash and pruritus. Unless an alternate etiology has been identified, signs or symptoms of dermatitis should be considered immune-mediated. Permanently discontinue ipilimumab in patients with Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations. Withhold ipilimumab dosing in patients with moderate to severe signs and symptoms.

Major

Ipilimumab (applies to ipilimumab) endocrinopathies

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypothyroidism, Adrenal Insufficiency, Hyperthyroidism

Immune-mediated endocrinopathies, including fatal cases, have occurred with ipilimumab therapy. Monitor clinical chemistries, adrenocorticotropic hormone (ACTH) level, and thyroid function tests at the start of treatment, before each dose, and as clinically indicated based on symptoms. Withhold ipilimumab dosing in symptomatic patients and consider referral to an endocrinologist.

Major

Ipilimumab (applies to ipilimumab) enterocolitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Diarrhea/Enterocolitis/Gastroenteritis, Inflammatory Bowel Disease

Immune-mediated enterocolitis, including fatal cases, have occurred with ipilimumab therapy. It is recommended to withhold ipilimumab dosing in patients with moderate enterocolitis and institute appropriate measures. Ipilimumab must be permanently discontinued in patients with severe enterocolitis and appropriate measures should be initiated.

Major

Ipilimumab (applies to ipilimumab) hepatitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Immune-mediated hepatitis, including fatal cases, has occurred with ipilimumab therapy. In patients with hepatotoxicity, rule out infectious or malignant causes and increase frequency of liver function test monitoring until resolution. Ipilimumab must be permanently discontinued in patients with Grade 3 to 4 hepatotoxicity and appropriate measures should be taken. Withhold ipilimumab in patients with Grade 2 hepatotoxicity.

Major

Ipilimumab (applies to ipilimumab) neuropathies

Major Potential Hazard, High plausibility. Applicable conditions: Autonomic Neuropathy, Guillain-Barre Syndrome

Immune-mediated neuropathies, including fatal cases, have occurred with ipilimumab therapy. Ipilimumab must be permanently discontinued in patients with severe neuropathy (interfering with daily activities) such as Guillain-Barré-like syndromes and appropriate measures should be initiated. Withhold ipilimumab dosing in patients with moderate neuropathy (not interfering with daily activities).

Major

Ipilimumab (applies to ipilimumab) ocular disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Permanently discontinue ipilimumab in patients with immune-mediated ocular disease that is unresponsive to local immunosuppressive therapy.

Moderate

Ipilimumab (applies to ipilimumab) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effect of hepatic impairment on the clearance of ipilimumab was evaluated in patients with mild hepatic impairment. No clinically important differences in the clearance of ipilimumab were found between patients with mild hepatic impairment and patients with normal hepatic function. Ipilimumab has not been studied in patients with moderate or severe hepatic impairment.

Ipilimumab drug interactions

There are 136 drug interactions with ipilimumab

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.